WINSTON SALEM, NC (
TheStreet) -- Why is mutual fund giant Fidelity and a well-known healthcare hedge fund buying more
(TRGT) despite the company's miserable drug development track record?
The answer: Alzheimer's disease. More specifically, there's a drug sitting in Targacept's pipeline that could one day treat Alzheimer's and maybe schizophrenia, too. Billion-dollar plus markets, both.
Targacept shares trade at $4.31 even though the company has $205 million in cash on hand, worth roughly $6 per share. At that steep discount to cash value, Targacept shareholders get the Alzheimer's/schizophrenia drug, known as TC-5619, essentially for free.
Fidelity Investments owns 5 million shares of Targacept, including 1.2 million shares acquired in the second quarter, according to CapitalIQ. BVF Partners, run by hedge fund manager Mark Lampert, disclosed a 3.6 million-share ownership stake in Targacept on Sept. 10. Since May, Lampert has doubled the size of his position in Targacept, according to regulatory filings.At this point, you're shaking your head, or laughing out loud. Alzheimer's drugs, no matter how promising, all fail in the end. Pfizer (PFE), Elan (ELN), Eli Lilly (LLY) and Johnson & Johnson (JNJ) have taught us that lesson well. And Targacept? The company whose depression drug blew up because it ran clinical trials in India, sending shares plummeting 80% in 2011 and another 23% this year? C'mon. . . All true, but here's the interesting bit about TC-5619: The drug's mechanism by which it's supposed to improve cognition is shared by another drug owned by privately held EnVivo Pharmaceuticals. Better yet, the EnVivo drug, EVP-6124, has already posted positive data in both Alzheimer's and schizophrenia. Most recently In July, EnVivo announced positive results from a six-month, double blind, phase IIb study that evaluated EVP-6124 in patients with mild to moderate Alzheimer's. Treatment with EVP-6124 resulted in statistically significant improvements in cognition and clinical function -- hitting on both of the study's co-primary endpoints.
>To contact the writer of this article, click here: Adam Feuerstein. >To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein. >To submit a news tip, send an email to: email@example.com. Follow TheStreet on Twitter and become a fan on Facebook.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV